MARKET WIREYahoo • 11d ago
FMS Launches multiFiltratePRO System for U.S. Patients With Acute AKIFresenius Medical Care launches multiFiltratePRO kidney therapy system in the United States, expanding critical care options and growth opportunities.
Why FMS Stock dropped -2.85% Today — RQD Quant Desk Flash
$22.47 -2.85% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $22.31
Fresenius Medical Care AG American (FMS) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D+ • SELL / AVOID
Cap $12.55B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on FMS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is FMS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Fresenius Medical Care AG American (NYSE: FMS) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $22.47 (-2.85% 1D, market cap $12.55B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, FMS ranks #186 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does FMS compare to DVA and SHC in the Health Care sector?
▼
Within the Health Care sector (Misc Health and Biotechnology Services), FMS carries a Roarable D+ (57/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, DVA (DaVita Inc.) holds a B grade (74/100 RQD, P/E 11.4x, ROIC 29.2%, cap $11.79B) and SHC (Sotera Health Company) posts a D grade (49/100 RQD, P/E 68.5x, ROIC 3.1%, cap $5.18B). Among the 5-stock peer group, DVA leads on earnings multiple (11.4x) while DVA leads on capital efficiency (29.2% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for FMS?
▼
For Fresenius Medical Care AG American (FMS), key quantitative strengths include Clean SEC annual filing review with no major hidden accounting time-bombs and sector rank #186 in Health Care, while primary risk factors center on Sensitive to high interest rates and tighter Federal Reserve market liquidity and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $22.31 (-0.70%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 6.9% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 57/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.2% avg 90D alpha vs SPY • 52.2% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D+
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D+ · Rk C
Each axis scored 0–20
12M PRICE TARGET CONE-0.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for FMS)Realized 20D OHLCV Swing Band: ±4.4%
Deterministic 5-Pillar Attribution (57/100 Composite)
🔍 WHY FMS SCORES 57/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (28% of score)
Altman Z-Score 3.74 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (21% of score)
SEC XBRL Trailing 12 Months: 6.9% FCF Margin ($277.4M FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning8/20 pts (-12 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$21.54+0.1% Next Q
49
Q2 (-2Q)Grade C-$21.56+4.9% Next Q
52
Q3 (-1Q)Grade C-$22.62-0.7% Next Q
54
CurrentGrade D+$22.47-0.2% Hist 90D α
57
Trajectory: D (49) → D+ (57)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the FMS Bull Thesis Could Fail
Even with a 57/100 (D+) score, FMS faces multiple-compression risk if 32.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Sensitive to high interest rates and tighter Federal Reserve market liquidity.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($22.35) or 200D SMA ($22.89) invalidates the momentum regime and cuts Target Base ($22.37) toward Bear Floor ($17.45).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $FMS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “FMS Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why FMS Stock dropped -2.85% Today — RQD Quant Desk Flash
Fresenius Medical Care AG American (FMS) dropped -2.85% to $22.47, trading at 37% of its 52-week range ($20.02 – $26.66). Stretched risk/reward at 33x P/E (10% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 37% of its 52-week range ($20.02 – $26.66) with RSI-14 at 50.8 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±4.4% around $22.47 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 52% gross margin and $277.4M annual free cash flow.
Live FMS Headlines & Catalysts
MARKET WIREBenzinga • 12d ago
Reported Earlier, Fresenius Medical Care Launches multiFiltratePRO In US After FDA Clearance, Expanding Continuous Kidney Replacement Therapy Options For Acute Kidney InjuryExpands access to Fresenius Medical Care's globally established portfolio of advanced kidney replacement therapies in the U.S.FDA clearance of multiFiltratePRO and approval of dedicated solutions expand continuous
RISK WATCHYahoo • 12d ago
Fresenius Medical Care Brings Kidney Care Innovation to Critical Care Patients with U.S. Launch of multiFiltratePRO™Fresenius Medical Care, the world's leading provider of products and services for people with kidney disease, today announced the U.S. launch of the multiFiltratePRO System for critically ill patients with acute kidney i
MARKET WIREBenzinga • 14d ago
'HHS releases new kidney care plan' - Axios Exclusivehttps://www.axios.com/2026/10/20/kidney-care-plan-kennedy
MARKET WIREYahoo • 15d ago
Fresenius Medical Care presents new evidence and innovations advancing kidney care at ASN Kidney Week 2026Fresenius Medical Care (FME), the world's leading provider of products and services for people with kidney disease, presents new research and evidence-driven innovations aimed at improving patient outcomes during the Ame
CATALYSTYahoo Finance • 27d ago
Shervin J. Korangy appointed CEO of Fresenius Medical Care to lead the next phase of strategic development and long-term profitable growthFresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced that Shervin J. Korangy (51) will become Chief Executive Officer (CEO) and Chair of
CATALYSTYahoo Finance • 35d ago
Fresenius Medical Care Reshapes China Portfolio for Long-Term GrowthFMS refines its China strategy around advanced dialysis and critical-care technologies, with 110M euros in one-time costs.
CATALYSTYahoo Finance • 39d ago
Fresenius Medical Care Refines China Commercial Strategy with a Focus on Long-Term Growth and Market LeadershipYahoo Finance coverage on FMS stock catalysts, institutional flow, and earnings outlook.
RISK WATCHYahoo Finance • 56d ago
FDA Slams Fresenius Over Leaking Dialysis Bags, Warns of Potentially Life-Threatening RiskThe U.S. Food and Drug Administration (FDA) on Tuesday issued a warning letter to Fresenius Medical Care AG & Co. KGaA’s Fresenius USA Manufacturing following a March 2026 inspection at its Ogden, Utah production facilit
CATALYSTYahoo Finance • 60d ago
Can Fresenius Medical's 5008X Rollout Drive the Next Growth Phase?Fresenius Medical is scaling its 5008X rollout across U.S. clinics, creating growth potential despite volume, reimbursement and rollout-cost pressures.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring FMS)
- ✓Walkthrough of FMS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
FMS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -0.79%▼ DESCENDING CHANNEL
2026-11-03O $23.13H $23.13L $22.47C $22.47VOL 968.0K
RES: $23.11SUP: $19.65SMA50: $22.35SMA200: $22.89
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
FMS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
25.3%/yr Implied 5Y Growth
vs. -3.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on FMS today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for FMS. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for FMS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (FMS)
Health Care Rank #186 of 1015
⚔️ DVA vs FMS Full Matrix →
1. Head-to-Head Health Care Peer Comparison (FMS vs. DVA, SHC, PGNY, AGL)
Industry: Misc Health and Biotechnology Services (10 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Fresenius Medical Care AG American (FMS) ranks #186 by composite RQD confidence (57/100, grade D+) and #89 by equity capitalization ($12.55B). Within this direct 5-issuer industry benchmark cohort, DVA leads on earnings valuation at 11.4x trailing P/E, while DVA leads on capital efficiency and profitability with 29.2% ROIC and — gross margin. PGNY currently holds the highest overall quantitative score in the immediate peer group at 79/100 (B+) compared with FMS at 57/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| FMS
ACTIVE
Fresenius Medical Care AG American | D+ | 57/100 | 32.8x | — | 9.9% | -2.85% | $12.55B | Benchmark Subject |
| DVA DaVita Inc. | B | 74/100 | 11.4x | — | 29.2% | -3.01% | $11.79B | /dva-vs-fms → |
| SHC Sotera Health Company | D | 49/100 | 68.5x | 55.5% | 3.1% | -2.94% | $5.18B | /shc-vs-fms → |
| PGNY Progyny Inc. | B+ | 79/100 | 37.2x | 23.6% | 16.7% | +2.78% | $2.24B | /pgny-vs-fms → |
| AGL agilon health inc. | D- | 36/100 | — | — | -35.0% | -1.21% | $1.43B | /agl-vs-fms → |
2. FMS Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTFresenius Medical Care AG American (FMS) operates in Misc Health and Biotechnology Services (Health Care) with an equity capitalization of $12.55B, trailing P/E of 32.8x, forward P/E of 30.5x, and EV/EBITDA of 21.0x. Operating profitability registers a gross margin of —, operating margin of 13.9%, net profit margin of 10.9%, ROIC of 9.9%, and free cash flow yield of 2.21%, alongside an Altman Z-Score of 3.74 and Piotroski F-Score of 7/9.
3. FMS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs FMS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Fresenius Medical Care AG American (NYSE: FMS) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $22.47 (-2.85% 1D, market cap $12.55B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, FMS ranks #186 in composite RQD confidence.
How does FMS compare to DVA and SHC in the Health Care sector?
Within the Health Care sector (Misc Health and Biotechnology Services), FMS carries a Roarable D+ (57/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, DVA (DaVita Inc.) holds a B grade (74/100 RQD, P/E 11.4x, ROIC 29.2%, cap $11.79B) and SHC (Sotera Health Company) posts a D grade (49/100 RQD, P/E 68.5x, ROIC 3.1%, cap $5.18B). Among the 5-stock peer group, DVA leads on earnings multiple (11.4x) while DVA leads on capital efficiency (29.2% ROIC).
What are the biggest fundamental strengths and SEC risk factors for FMS?
For Fresenius Medical Care AG American (FMS), key quantitative strengths include Clean SEC annual filing review with no major hidden accounting time-bombs and sector rank #186 in Health Care, while primary risk factors center on Sensitive to high interest rates and tighter Federal Reserve market liquidity and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
Where is FMS trading relative to its 50-day, 200-day, and 52-week technical levels?
FMS last traded at $22.47 (-2.85% on volume of 967,987 shares), positioning the stock +0.54% above its 50-day simple moving average ($22.35) and -1.83% below its 200-day simple moving average ($22.89). Across its 52-week range of $20.02 to $26.66, FMS sits at the 36.9% percentile with a 14-day RSI of 50.8 (NEUTRAL RANGE) and an implied next-earnings move of ±4.4% ($21.48 to $23.46).
ROARABLE RATING BRIEF • RQD 57/100 (D+)
✓ SEC XBRL & RQD VERIFIED
FMS — Fresenius Medical Care AG American: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03
1. Roarable Rating Brief: What This Means to a Prospective Investor
Fresenius Medical Care AG American (FMS) earns a live Roarable RQD composite score of 57/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $22.47 (-2.85% 1D, market capitalization $12.55B).
- Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of 9.9%, gross margin of —, operating margin of 13.9%, and free cash flow yield of 2.21%.
- Whale 13F & Options Flow (8/20) + Insider Conviction (12/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (9/20) + Forensic Balance Sheet (16/20): Incorporates a 0.90x equity beta, Altman Z-Score of 3.74, Piotroski F-Score of 7/9, and Debt/Equity of 0.39x.
2. Business Model, Unit Margins & SEC Financial Trajectory
Fresenius Medical Care AG American (FMS) is a NYSE-listed issuer in the Health Care sector, within the Misc Health and Biotechnology Services industry..9B. — The products, customers, and revenue model are not described in the source data.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D+ • RQD 57/100): Clean SEC annual filing review with no major hidden accounting time-bombs. Free cash flow yield of 2.21% and institutional whale pillar of 8/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $20.02 – $26.66 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh 32.8x trailing P/E and 21.0x EV/EBITDA against 13.9% operating margins and a 0.90x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be identified from the source data.
- Key Question #1: Can FMS sustain or expand its 13.9% operating margin and 9.9% ROIC against Misc Health and Biotechnology Services peers over the next 4 quarters?
- Key Question #2: Will free cash flow conversion (2.21% FCF yield) strengthen balance-sheet liquidity (Altman Z-Score 3.74) toward the $26.66 52-week high?
- Key Question #3: How sensitive is FMS's 30.5x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.90x)?
FMS Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Fresenius Medical Care AG American (FMS) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo • 11d ago
FMS Launches multiFiltratePRO System for U.S. Patients With Acute AKI Fresenius Medical Care launches multiFiltratePRO kidney therapy system in the United States, expanding critical care options and growth opportunities.
🟡 MARKET WIRE Benzinga • 12d ago
Reported Earlier, Fresenius Medical Care Launches multiFiltratePRO In US After FDA Clearance, Expanding Continuous Kidney Replacement Therapy Options For Acute Kidney Injury Expands access to Fresenius Medical Care's globally established portfolio of advanced kidney replacement therapies in the U.S.FDA clearance of multiFiltratePRO and approval of dedicated solutions expand continuous
🔴 RISK WATCH Yahoo • 12d ago
Fresenius Medical Care Brings Kidney Care Innovation to Critical Care Patients with U.S. Launch of multiFiltratePRO™ Fresenius Medical Care, the world's leading provider of products and services for people with kidney disease, today announced the U.S. launch of the multiFiltratePRO System for critically ill patients with acute kidney i
🟡 MARKET WIRE Benzinga • 14d ago
'HHS releases new kidney care plan' - Axios Exclusive https://www.axios.com/2026/10/20/kidney-care-plan-kennedy
🟡 MARKET WIRE Yahoo • 15d ago
Fresenius Medical Care presents new evidence and innovations advancing kidney care at ASN Kidney Week 2026 Fresenius Medical Care (FME), the world's leading provider of products and services for people with kidney disease, presents new research and evidence-driven innovations aimed at improving patient outcomes during the Ame
🟢 CATALYST Yahoo Finance • 27d ago
Shervin J. Korangy appointed CEO of Fresenius Medical Care to lead the next phase of strategic development and long-term profitable growth Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced that Shervin J. Korangy (51) will become Chief Executive Officer (CEO) and Chair of
🟢 CATALYST Yahoo Finance • 35d ago
Fresenius Medical Care Reshapes China Portfolio for Long-Term Growth FMS refines its China strategy around advanced dialysis and critical-care technologies, with 110M euros in one-time costs.
🟢 CATALYST Yahoo Finance • 39d ago
Fresenius Medical Care Refines China Commercial Strategy with a Focus on Long-Term Growth and Market Leadership Yahoo Finance coverage on FMS stock catalysts, institutional flow, and earnings outlook.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
FMS Bull vs. Bear Conversation Board — What's Your Call at $22.47?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON FMS 🐻 33% BEARISH CONVICTION
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH
🎯 Target: $29.66 (+32.0%)
📌 Pinned Debate A 16/20 forensic balance sheet with an Altman Z-Score of 3.74 and a Piotroski F-Score of 7/9 signals financial strength.
Long FMS at $22.47 targeting $29.66. A 16/20 forensic balance sheet with an Altman Z-Score of 3.74 and a Piotroski F-Score of 7/9 signals financial strength.. Institutional whale score is 8/20 and the risk/reward vs. the $20.02 52-week low is skewed heavily in favor of bulls.
CapAlloc_Nerd 🐂 BULL
@TapeReader_Pro Agree on the RQD 57/100 quality, though with 0.9 beta I'm scaling in with half-size at $22.47 and keeping dry powder in case we test $20.90.
FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH
🎯 Target: $17.08 (-24.0%)
Spot @ $22.47 A 2.21% FCF yield against a 32.8 trailing P/E leaves thin cash returns to support a demanding valuation.
Fading this rally in FMS at $22.47. A 2.21% FCF yield against a 32.8 trailing P/E leaves thin cash returns to support a demanding valuation.. With a beta of 0.9 and the stock sitting at $22.47 (52-wk range $20.02–$26.42), the easy multiple expansion is already priced in.